News + Resources

Keep up with the latest

Featured

This Scientist Is Building Custom Gene-Editing Tools

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

CRISPR 2.0, the Next Generation

June 21, 2024

Aspen Ideas: Health

CRISPR 2.0, the Next Generation

June 21, 2024

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

TEDxBerkeley

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

Scribe Therapeutics Picks Cholesterol-Lowering As First In Vivo Gene Target

February 7, 2024

Scrip

Scribe Therapeutics Picks Cholesterol-Lowering As First In Vivo Gene Target

February 7, 2024

All Stories

News

CEO of Doudna spinout: Within five years, genome editors will have a 'really big impact' on patients' lives

August 12, 2022

Endpoints News

Read Now

Press Release

CEO of Doudna spinout: Within five years, genome editors will have a 'really big impact' on patients' lives

August 12, 2022

Endpoints News

Read Now

News

Scribe Therapeutics converting an Alameda shipway into a lab

July 30, 2022

The Real Deal

Read Now

Press Release

Scribe Therapeutics converting an Alameda shipway into a lab

July 30, 2022

The Real Deal

Read Now

News

Scribe Therapeutics Announces Expansion of San Francisco Bay Area Headquarters, 3 Key Senior Hires

July 26, 2022

Read Now

Press Release

Scribe Therapeutics Announces Expansion of San Francisco Bay Area Headquarters, 3 Key Senior Hires

July 26, 2022

Read Now

News

Scribe Therapeutics to Participate in SVB Securities Biopharma Private Company Connect

July 15, 2022

Read Now

Press Release

Scribe Therapeutics to Participate in SVB Securities Biopharma Private Company Connect

July 15, 2022

Read Now

News

How Jennifer Doudna's Life Has Changed Since Discovering CRISPR 10 Years Ago

July 1, 2022

TIME

Read Now

Press Release

How Jennifer Doudna's Life Has Changed Since Discovering CRISPR 10 Years Ago

July 1, 2022

TIME

Read Now

News

Innovators Under 35

June 29, 2022

MIT Technology Review

Read Now

Press Release

Innovators Under 35

June 29, 2022

MIT Technology Review

Read Now

News

Future of Epigenetic Medicine

July 22, 2024

FutureBites

Read Now

News

CRISPR 2.0, the Next Generation

June 21, 2024

Aspen Ideas: Health

Read Now

News

CRISPR technology’s next wave: Eight companies to watch in 2024

June 20, 2024

Labiotech

Read Now

News

Top Five Privately Held Gene Editing Therapy Companies

May 31, 2024

Genetic Engineering & Biotechnology News

Read Now

News

Women @ RopesTalk: Conversation with Svetlana Lucas, Scribe Therapeutics

May 22, 2024

Ropes & Gray

Read Now

News

DNA: Cutting the Future of Genome Editing

May 2, 2024

The Biomedical Scientist

Read Now

Press release

Scribe Therapeutics Presents Data on its X-Editing Technologies at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 19, 2023

Read Now

Press release

Scribe Announces Collaboration with Prevail, a Wholly Owned Subsidiary of Lilly, to Accelerate In Vivo CRISPR-based Genetic Medicines for Neurological and Neuromuscular Diseases

May 16, 2023

Read Now

Press release

Scribe Therapeutics Announces Oral Presentation at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 2, 2023

Read Now

Press release

Scribe Therapeutics to Participate in Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days

March 31, 2023

Read Now

Press release

Scribe Therapeutics to Participate in Four Upcoming Conferences

November 17, 2022

Read Now

Press release

Scribe Therapeutics to Participate in Upcoming Investor Conferences

September 29, 2022

Read Now

Publications

CasX enzymes comprise a distinct family of RNA-guided genome editors

February 4, 2019

Nature

Read Now

Publications

Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes

May 1, 2017

Nature Biotechnology

Read Now

Publications

Targeted gene knock-in by homology-directed genome editing using Cas9 ribonucleoprotein and AAV donor delivery

March 2, 2017

Nucleic Acids Research

Read Now

Publications

Profiling of engineering hotspots identifies an allosteric CRISPR-Cas9 switch

June 1, 2016

Nature Biotechnology

Read Now

Publications

Multi-reporter selection for the design of active and more specific zinc-finger nucleases for genome editing

January 7, 2016

Nature Communications

Read Now

Publications

Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery

December 15, 2014

eLife

Read Now

Publications

Programmable RNA recognition and cleavage by CRISPR/Cas9

December 11, 2014

Nature

Read Now

Publications

MicroRNA-mediated switching of chromatin-remodelling complexes in neural development

July 30, 2009

Nature

Read Now